Skip to main content
    I

    Immunic Inc (IMUX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $7.23
    -0.29 (-3.86%)

    Market Cap: $102.61M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Immunic Inc (IMUX) Earnings: Report Dates and Results

    Updated Nov 13, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Immunic (IMUX) is expected to report earnings on Feb 24, 2027. In the quarter ended Sep 30, 2026, Immunic reported EPS of -$0.99, below the -$0.82 estimate. It beat the EPS estimate in 2 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    38%(15/39)
    Avg Surprise
    -6.12%

    Upcoming Estimates

    Reports Feb 24, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$0.82
    Range-$1.23 - -$0.60
    13 analysts
    Revenue Consensus
    N/A
    RangeN/A
    13 analysts

    Next Report

    IMUX has an expected report date of Feb 24, 2027.

    IMUX Earnings Call

    The latest IMUX earnings call transcript on file is labeled 2024Q3.

    Read the 2024Q3 transcript

    Earnings History

    Of the 39 quarters below that had an estimate, IMUX beat 15, missed 21 and matched 3. The widest gap in the table came in the quarter ended Jun 30, 2019, when EPS landed 123.53% below the estimate.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReported
    Sep 30, 2026-$0.99-$0.82-$2.58 - -$0.67-20.73%MissN/A127 up, 3 downNov 13, 2026
    Jun 30, 2026-$0.80-$1.24-$2.41 - -$0.63+35.48%BeatN/A102 up, 4 downAug 11, 2026
    Mar 31, 2026-$1.08-$0.96-$2.00 - -$0.50-12.50%MissN/A72 up, 2 downMay 13, 2026
    Dec 31, 2025-$0.12-$0.10-$0.26 - -$0.07-20.00%MissN/A90 up, 1 downFeb 26, 2026
    Sep 30, 2025-$1.30-$1.77-$2.70 - -$1.10+26.55%BeatN/A92 up, 3 downNov 13, 2025
    Jun 30, 2025-$0.20-$0.18-$0.26 - -$0.05-11.11%MissN/A64 up, 1 downAug 7, 2025
    Mar 31, 2025-$0.25-$0.25-$0.26 - -$0.160.00%In lineN/A71 up, 1 downMay 15, 2025
    Dec 31, 2024-$2.50-$2.38-$2.60 - -$2.20-5.04%MissN/A60 up, 6 downMar 31, 2025
    Sep 30, 2024-$2.40-$2.18-$2.30 - -$1.90-10.09%MissN/A50 up, 0 downNov 7, 2024
    Jun 30, 2024-$2.10-$2.33-$2.40 - -$2.20+9.87%BeatN/A30 up, 0 downAug 8, 2024
    Mar 31, 2024-$3.00-$2.65-$3.20 - -$2.30-13.21%MissN/A50 up, 0 downMay 8, 2024
    Dec 31, 2023-$0.48-$0.51-$0.56 - -$0.43+5.88%BeatN/A40 up, 0 downFeb 22, 2024
    Sep 30, 2023-$5.10-$5.07N/A-0.59%MissN/A40 up, 0 downNov 14, 2023
    Jun 30, 2023-$5.40-$5.12-$5.80 - -$4.50-5.47%MissN/A40 up, 0 downAug 3, 2023
    Mar 31, 2023-$5.80-$4.80-$6.00 - -$4.50-20.83%MissN/A40 up, 0 downMay 11, 2023
    Dec 31, 2022-$5.88-$7.42-$13.90 - -$3.90+20.75%BeatN/A41 up, 1 downFeb 23, 2023
    Sep 30, 2022-$6.90-$6.95-$7.00 - -$5.60+0.72%BeatN/A60 up, 0 downNov 3, 2022
    Jun 30, 2022-$7.20-$7.30-$8.40 - -$6.40+1.37%BeatN/A50 up, 0 downAug 4, 2022
    Mar 31, 2022-$7.40-$7.57-$9.00 - -$7.00+2.25%BeatN/A70 up, 0 downMay 10, 2022
    Dec 31, 2021-$0.72-$0.76-$0.99 - -$0.66+5.26%BeatN/A80 up, 0 downFeb 24, 2022
    Sep 30, 2021-$7.60-$7.52-$9.40 - -$5.90-1.06%MissN/A80 up, 1 downNov 4, 2021
    Jun 30, 2021-$8.20-$6.67-$7.80 - -$3.70-22.94%MissN/A8N/AAug 6, 2021
    Mar 31, 2021-$8.14-$6.85-$7.40 - -$6.00-18.83%MissN/A7N/AMay 6, 2021
    Dec 31, 2020-$0.46-$0.60-$0.75 - -$0.28+23.33%BeatN/A6N/AFeb 26, 2021
    Sep 30, 2020-$7.00-$6.47-$7.70 - -$5.50-8.19%MissN/A7N/ANov 5, 2020
    Jun 30, 2020-$9.00-$7.27-$8.00 - -$5.70-23.80%MissN/A4N/AAug 2, 2020
    Mar 31, 2020-$0.79-$0.95-$0.96 - -$0.95+16.84%BeatN/A2N/AMay 8, 2020
    Dec 31, 2019-$7.50-$7.60-$7.60 - -$7.60+1.32%BeatN/A1N/AMar 16, 2020
    Sep 30, 2019-$8.20-$6.50-$6.90 - -$6.50-26.15%MissN/A2N/ANov 7, 2019
    Jun 30, 2019-$15.20-$6.80N/A-123.53%MissN/AN/AN/AAug 8, 2019
    Mar 31, 2019-$0.91-$0.59-$0.59 - -$0.59-53.39%MissN/A1N/AApr 10, 2019
    Dec 31, 2018-$2.40-$0.14N/AN/AN/AN/AN/AN/AMar 4, 2019
    Sep 30, 2018-$11.20-$11.20N/A0.00%In lineN/AN/AN/ANov 7, 2018
    Jun 30, 2018-$12.00-$13.20N/A+9.09%BeatN/AN/AN/AAug 7, 2018
    Mar 31, 2018-$13.60-$13.60N/A0.00%In lineN/AN/AN/AMay 8, 2018
    Dec 31, 2017-$14.00-$12.40N/A-12.90%MissN/AN/AN/AMar 13, 2018
    Sep 30, 2017-$12.00-$12.80N/A+6.25%BeatN/AN/AN/AOct 25, 2017
    Jun 30, 2017-$11.60-$14.13N/A+17.91%BeatN/AN/AN/AAug 3, 2017
    Mar 31, 2017-$15.60-$14.60N/A-6.85%MissN/AN/AN/AMay 9, 2017
    Dec 31, 2016-$14.80-$14.20N/A-4.23%MissN/AN/AN/AMar 7, 2017
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$1.87, after -$10.00 the year before. It was -$52.00 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$1.87N/A
    Dec 31, 2024-$10.00N/A
    Dec 31, 2023-$16.78N/A
    Dec 31, 2022-$27.38N/A
    Dec 31, 2021-$24.66N/A
    Dec 31, 2020-$17.25N/A
    Dec 31, 2019-$31.81N/A
    Dec 31, 2018-$39.20N/A
    Dec 31, 2017-$53.20N/A
    Dec 31, 2016-$52.00N/A

    Earnings Calls

    The only earnings call listed below, 2024Q3 for the period ended Sep 30, 2024, runs about 6,000 words across 8 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2024Q3Sep 30, 20245,9798

    2024Q3 Earnings Call

    Opening remarks

    Jessica Breu Vice President, Investor Relations and Communications Good morning, and welcome to Immunic’s Third Quarter 2024 Earnings Call. My name is Jessica Breu, Vice President, Investor Relations and Communications at Immunic. I will also be the moderator today. Speaking on the call are Dr. Daniel Vitt, our Chief Executive Officer, Glenn Whaley, our Chief Financial Officer; as well as Jason Tardio, our President and Chief Operating Officer. Please note that all participants will be in listen-only mode, and this event is being recorded. After today’s presentation, there will be an opportunity to ask questions. Before we begin, I would like to remind you that this presentation may contain forward-looking statements. Such statements can be identified by words such as may, will, expect, anticipate, estimate, or words with a similar meaning. And, such statements involve a number of risks and uncertainties that could cause Immunic’s actual results to differ materially from those discussed here. Please note that these forward-looking statements reflect Immunic’s opinions only as of the date of this presentation, and it undertakes no obligation to revise or publicly release the result of any revision to these forward-looking statements in light of new information or future events. Please refer to Immunic’s SEC filings for a more detailed description of the risk factors that may affect Immunic’s results and these forward-looking statements. I would now like to turn the call over to our CEO, Dr. Daniel Vitt, to begin the presentation. Daniel?

    Daniel Vitt CEO Thank you, Jessica. I would also like to welcome everybody to today’s Q3 2024 earnings call. Earlier this morning, we announced our financial results for the third quarter and nine months ended September 30, 2024. During the call today, we will walk through our third quarter 2024 achievements and subsequent highlights, financial and operating results as well as our clinical development programs, including anticipated upcoming milestones. As Jessica noted, after the presentation, you will have the opportunity to ask questions. Let’s start with the review of our third quarter 2024 and subsequent highlights. In July, our management team was strengthened with the addition of Jason Tardio, as President and Chief Operating Officer, bringing with him a wealth of experience launching and commercializing multiple sclerosis drugs for major biotechnology and pharmaceutical companies. Jason has already proven to be invaluable, leading internal efforts to prepare for the potential commercialization of vidofludimus calcium. Jason also has been collaborating closely with Patrick Walsh, our Chief Business Officer, to prepare the company for a range of potential partnership outcomes for vidofludimus calcium as well as our other drug candidates, where we are leveraging his extensive partnering experience. Additionally, Werner Gladdines was promoted to Chief Development Officer.

    Frequently Asked Questions About IMUX

    When is Immunic's next earnings date?

    Immunic's next earnings report is expected for Feb 24, 2027.

    Did IMUX beat earnings estimates last quarter?

    No. Immunic reported EPS of -$0.99 for the quarter ended Sep 30, 2026, below the -$0.82 estimate by 20.73%.

    What EPS do analysts expect from IMUX next quarter?

    The consensus EPS estimate for Immunic for the quarter ending Dec 31, 2026 is -$0.82 from 13 analysts, with estimates from -$1.23 to -$0.60.

    How often does IMUX beat earnings estimates?

    Immunic beat the EPS estimate in 2 of the last 8 quarters, with an average surprise of -0.92%.